Four sequential stages move a candidate therapy from a small first-in-human safety test through large-scale efficacy studies and into long-term post-approval monitoring. Each stage answers a different scientific question while building on the evidence gathered in the one before it. Because only about 10% of drugs entering Phase I ever reach pharmacy shelves, the path from lab to prescription is narrower than most headlines suggest.
This walkthrough explains each stage in plain language, describes who participates and what researchers measure, and shows why the order matters when you’re weighing a treatment decision or considering enrollment in a study.
The Drug Development Pipeline Before Human Testing Begins
Every pill, injection, or infusion that ends up at a pharmacy counter starts years earlier in a lab, where chemists test thousands of compounds against a biological target. Fewer than 1% of those early candidates survive the first filters, which usually screen for potency, stability, and basic toxicity in cell cultures and animal models. Preclinical research can take three to six years, and roughly 9 out of 10 experimental treatments quietly disappear during this window.
Before any human can receive an experimental drug, the sponsor must file an Investigational New Drug (IND) application with the FDA. That document compiles every preclinical result, manufacturing detail, and proposed study protocol so regulators can decide whether the candidate is safe enough to test in people. The FDA typically responds within 30 days, and a clinical hold can stop the program in its tracks if safety concerns are unresolved.
Ethics Review and Informed Consent
Before a single volunteer is enrolled, an Institutional Review Board (IRB) independently evaluates the trial design, risk-benefit profile, and the informed consent document. IRBs include doctors, statisticians, ethicists, and community members who can pause, modify, or reject a study. Volunteers must sign consent forms explaining procedures, known risks, alternative treatments, and their right to withdraw at any time without losing access to standard care.
Tip: Search any trial on ClinicalTrials.gov to see the phase, sponsor, IRB approval status, and inclusion criteria before contacting a study site.
Phase I Trials Test Safety First in Small Groups
Phase I trials enroll 20 to 100 healthy volunteers to find the highest dose a person can tolerate without unacceptable side effects. Oncology trials are a common exception, where patients with the target disease participate from the start because giving a toxic compound to a healthy person would be unethical. Researchers escalate doses in small cohorts while watching for adverse events and measuring how the drug moves through the body through pharmacokinetic studies.
This stage typically lasts several months, making it the shortest phase but one of the most closely monitored. About two-thirds of candidates advance past Phase I, with attrition driven mainly by unacceptable toxicity at therapeutic doses rather than by lack of efficacy. Healthy volunteers in Phase I often receive compensation for time and travel, reflecting the demanding schedule of blood draws, EKGs, and overnight stays.
| Feature | Typical Range |
|---|---|
| Participants | 20 to 100 healthy volunteers |
| Duration | Several months |
| Primary Goal | Safety and tolerable dosage range |
| Key Measurements | Adverse events, pharmacokinetics, maximum tolerated dose |
| Approximate Advance Rate | ~65% move to Phase II |
Phase II Trials Begin Measuring Whether the Drug Actually Works
Phase II involves 100 to 300 participants who actually have the target condition, a meaningful shift from the healthy volunteers of Phase I. Researchers track whether the drug produces the intended biological or clinical effect while continuing to monitor safety signals across a broader, more representative population.
These trials run from several months up to two years and often include a control group receiving either a placebo or the current standard of care. Randomization helps ensure that observed differences reflect the drug rather than chance variation between patients. Success rates drop sharply here, with only about a third of candidates that enter Phase II advancing to the next stage, often because the effect size is too small to justify larger investment.
Phase IIa Versus Phase IIb
Sponsors frequently split Phase II into two sub-stages. Phase IIa focuses on dosing and early proof of concept, asking whether any signal of activity exists at all. Phase IIb refines the dose-response curve and confirms efficacy in a slightly larger group, setting up the design of the pivotal Phase III program.
Example: A new blood-pressure medication might enter Phase IIa with 60 patients across three dose levels, then expand in Phase IIb to 200 patients randomized against placebo to confirm which dose delivers the best balance of effect and tolerability before committing to a 2,000-patient Phase III trial.
Phase III Trials Scale Up to Confirm Effectiveness Against Standard Care
Phase III recruits 1,000 to 3,000 patients across multiple hospitals and often multiple countries, generating the pivotal evidence package submitted for marketing approval. These are the studies regulators scrutinize most carefully because their results determine whether a drug reaches the public.
Lasting one to four years, Phase III trials frequently use randomized, double-blind designs where neither the patient nor the treating physician knows who receives the experimental drug versus the comparator. This blinding minimizes bias and produces the most credible evidence of clinical benefit. By this point, the experimental treatment is compared against the current standard of care rather than just placebo, so patients in the control arm still receive the best known therapy.
| Aspect | Phase II | Phase III |
|---|---|---|
| Participants | 100 to 300 patients | 1,000 to 3,000 patients |
| Duration | Months to ~2 years | 1 to 4 years |
| Comparator | Placebo or standard care | Current standard of care |
| Primary Aim | Early efficacy and dose-finding | Confirm efficacy and monitor safety at scale |
| Advance Rate | ~33% move forward | ~60% of those entering gain approval |
Positive Phase III results form the core of a New Drug Application (NDA) or Biologics License Application (BLA) submitted to the FDA, along with manufacturing data, labeling proposals, and risk-management plans. A negative outcome, whether on efficacy, safety, or commercial grounds, usually ends the program.
Phase IV Surveillance Tracks Real-World Use After Approval
Phase IV begins only after regulators grant marketing authorization and the drug reaches the broader population. Because Phase III studies enroll only a few thousand carefully selected patients, rare side effects, drug interactions, and long-term risks often emerge only when millions of real-world prescriptions are written.
The FDA, the European Medicines Agency (EMA), and national pharmacovigilance programs such as the FDA’s MedWatch system collect spontaneous adverse event reports from clinicians, manufacturers, and consumers. Findings can lead to updated warning labels, new dosing guidelines, restricted indications, or, in rare cases such as rofecoxib (Vioxx) in 2004, withdrawal from the market.
Tip: Report any unexpected symptoms after starting a new medication to your prescriber and through the FDA MedWatch program; those reports feed the safety surveillance system.
What Trial Phases Mean for Patients Considering Participation
Each phase carries different risk profiles, time commitments, and potential benefits. Phase I and Phase II participants may access investigational therapies years before public availability, but your chance of personal benefit is lower than in later phases because efficacy is still uncertain. Phase III participants receive either a promising new treatment or the current standard of care, and the structured monitoring is often more intensive than routine clinical practice.
Understanding the phase helps you set realistic expectations about personal benefit versus contribution to science. Phase IV studies, sometimes called pragmatic or real-world studies, enroll patients who would use the drug anyway and focus on long-term outcomes in everyday settings.
Reading Eligibility Criteria on ClinicalTrials.gov
Each trial listing on ClinicalTrials.gov shows the phase, condition, sponsor, locations, and detailed inclusion and exclusion criteria. Eligibility criteria indicate which phase, condition, and patient population a study targets, and they often specify age ranges, prior treatments, organ function tests, and pregnancy status. Contacting the study coordinator listed in the record is the fastest way to confirm whether you qualify and what participation would involve.
Questions worth asking before enrolling include how many visits the trial requires, whether the study covers travel costs, what happens if you experience a side effect, and whether you can continue receiving the investigational drug after the trial ends if it appears to be helping you.
The Big Picture
The phased structure exists because history taught regulators and researchers that skipping steps costs lives. Each stage filters out unsafe or ineffective candidates while gathering the specific evidence needed for the next decision, from first-in-human dosing to global marketing authorization. Knowing where a candidate sits in this progression turns vague news about “promising new treatments” into a concrete estimate of how soon, and how confidently, a therapy might reach the people who need it.
FAQ
What are the four phases of clinical trials?
The four main phases are Phase I (small-scale safety and dosage testing), Phase II (initial efficacy and side-effect evaluation in patients), Phase III (large-scale randomized confirmation against standard care), and Phase IV (post-approval surveillance in the general population). You’ll move through them in order when you follow a candidate therapy from first-in-human dosing to long-term real-world use.
How long does each phase of a clinical trial last?
Phase I typically runs several months, Phase II runs from several months up to about two years, Phase III usually lasts one to four years, and Phase IV continues for as long as the drug remains on the market. Your personal time commitment in any one phase may fall anywhere inside that window, depending on the study design and how long you remain enrolled.
What is the difference between Phase II and Phase III clinical trials?
Phase II enrolls 100 to 300 patients to detect early signals of efficacy and refine dosing, while Phase III enrolls 1,000 to 3,000 patients to confirm the drug works better than current standard care and to detect less common side effects. You’ll notice the jump in scale, in geography, and in the rigor of the evidence regulators require before approval.
Why do clinical trials have phases?
Phasing protects volunteers by escalating exposure gradually, gives regulators staged evidence to review, and lets sponsors stop failing programs early, saving time, money, and patient risk. For you, that structure means each new question is answered only after the previous one is reasonably resolved.
What percentage of drugs pass Phase I clinical trials?
About 65% of drugs that enter Phase I advance to Phase II, but only around 10% of drugs entering Phase I ever receive FDA marketing approval, because failures continue to mount across later phases. Your takeaway: a clean Phase I readout is encouraging, but it is far from a guarantee the therapy will reach your pharmacy.
What is a Phase 0 clinical trial?
Giving subtherapeutic doses to a tiny group of participants,often just 10 to 15 people,a Phase 0 (exploratory) trial reveals how the drug moves through the body before committing to a full Phase I program. You may see Phase 0 listed on ClinicalTrials.gov, and it sits one rung below Phase I in the development ladder.
